This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 2
  • /
  • BMS announces positive topline results from second...
News

BMS announces positive topline results from second pivotal phase III POETYK PSO-2 psoriasis study showing superiority of deucravacitinib over placebo and Otezla .

Read time: 1 mins
Published:3rd Feb 2021
Bristol Myers Squibb announced positive results from POETYK PSO-2, the second pivotal Phase III trial evaluating deucravacitinib, a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of patients with moderate to severe plaque psoriasis. POETYK PSO-2 evaluated deucravacitinib 6 mg once daily and met both co-primary endpoints versus placebo , with significantly more patients achieving Psoriasis Area and Severity Index (PASI 75), defined as at least a 75 percent improvement of baseline PASI, and a static Physician's Global Assessment (sPGA) score of clear or almost clear (sPGA 0/1) after 16 weeks of treatment with deucravacitinib.The trial also met multiple key secondary endpoints, including showing deucravacitinib 6 mg once daily was superior to Otezla (apremilast) in the proportion of patients reaching PASI 75 and sPGA 0/1 at Week 16 . The overall safety profile of deucravacitinib in POETYK PSO-2 remains consistent with previously reported results and consistent with the mechanism of action of deucravacitinib. POETYK PSO-2 is the second of two global Phase III studies demonstrating superiority of once daily deucravacitinib compared to placebo and Otezla in patients with moderate to severe plaque psoriasis . Positive topline results from the first Phase III trial, POETYK PSO-1, were announced in November 2020. The company and key investigators will complete a full evaluation of the POETYK PSO-2 data and share the detailed results at a future medical meeting. The trial also met multiple key secondary endpoints, including showing deucravacitinib 6 mg once daily was superior to Otezla (apremilast) in the proportion of patients reaching PASI 75 and sPGA 0/1 at Week 16. The overall safety profile of deucravacitinib in POETYK PSO-2 remains consistent with previously reported results and consistent with the mechanism of action of deucravacitinib.
Condition: Psoriasis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.